Acuity Pharmaceuticals Company
Acuity Pharmaceuticals is a pharmaceutical company that is focused on the treatment and prevention of ophthalmic diseases. It develops treatments for age-related macular degeneration and diabetic retinopathy. The company offers Cand5, a clinical compound that is able to shut down vascular endothelial growth factor. Acuity Pharmaceuticals was acquired by OPKO Health in June 2011. Acuity Pharmaceuticals was founded in 2007 and is based in Philadelphia, Pennsylvania.